|
||
| |||||||
|
|
Melbourne, Australia 23 May 2006, Phosphagenics Limited (“Phosphagenics”), the Australian Stock Exchange (ASX : POH) and the London Stock Exchange’s Alternative Investment Market (AIM : PSG) listed pharmaceutical and nutraceutical company, today announced that it has commenced the building of a production plant in Melbourne. The new facility, added to the existing unit owned by the Company in Ontario and operated under a contract-manufacturing arrangement, will permit a material increase in the Company’s ability to manufacture tocopheryl phosphates, vital components of many of its pharmaceutical and nutraceutical products. It will also provide the Company with manufacturing capabilities to meet anticipated future supply requirements. The new facility, expected to be commercially ready by the end of 2006, will be a scaled-up version of the pilot plant used successfully in the initial development of Phosphagenics' proprietary phosphorylation process. On completion the facility will have an annual capacity of 100 tonnes of high purity tocopheryl phosphates with an estimated wholesale value of $A25 million, although the Company does not expect to utilize all of this capacity in the immediate future. The budgeted cost for the upscale including all ancillary equipment is $A500,000, with all manufacturing equipment complying with Food Standards Australia New Zealand criteria. Ian Pattison, Chief Operating Officer of Phosphagenics, said: “The new plant will demonstrate our capability to manufacture on a commercial scale for current and future licensing partners. On completion it will also allow us to step up manufacturing output as the markets for Phosphagenics' products develop.” ENDS Notes to Editors
About
Phosphagenics
Phosphagenics is based in Melbourne, Australia. Its shares are listed on the Australian Stock Exchange (POH) and the London Stock Exchange's Alternative Investment Market (PSG). An American Depository Receipts-Level 1 facility has been established in the US with the Bank of New York (PPGNY) for the trading of the Company’s shares in the US ‘Over the Counter’ market. Further information regarding Phosphagenics can be found at www.phosphagenics.com. Phosphagenics has existing commercial agreements with Zila and ISP for the dietary supplement and personal care markets, and has announced joint development programmes with Alza Corporation and Nestlé Nutrition. For further information please contact: Australia: Phosphagenics Limited : Harry Rosen, Managing Director Telephone: +61 3 9605 5900
Northbank Communications: Rowan Minnion / Justine Lamond Telephone: +44 7886 8150 r.minnion@northbankcommunications.com , j.lamond@northbankcommunications.com |
|
| ||||||||
